News | EP Lab | May 18, 2018

Myocarditis is an Under-recognized Etiology of Symptomatic Premature Ventricular Arrhythmia

Findings of the MAVERIC Registry presented at the Heart Rhythm 2018

Myocarditis is an Under-recognized Etiology of Symptomatic Premature Ventricular Arrhythmia (PVCs). #HRS #HRS2018

May 18, 2018 — A significant number of patients with symptomatic premature ventricular contractions (PVCs) have underlying myocarditis identified by FDG-PET, and treatment with immunosuppressive therapy may significantly impact outcomes. This was a key finding in a review of the Myocarditis and Ventricular Arrhythmia (MAVERIC) Registry presented at Heart Rhythm 2018, the Heart Rhythm Society’s 39th Annual Scientific Sessions. 

Symptomatic premature ventricular contractions (PVCs) are common in clinical practice. Myocarditis often goes unrecognized with a potential for continued disease progression & cardiomyopathy. PVCs may be marker of underlying myocarditis; identification and Rx of myocarditis may improve outcomes.

The registry data includes 107 patients with symptomatic PVCs and no underlying ischemic heart disease (IHD). These patients had viral and autonomic serology, 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), cardiac magnetic resonance imaging (CMR) and myocardial biopsy. Patients with focally positive PET scans were labelled as mycarditis and were treated with immunosuppressive therapy (IST) as first line therapy, followed by ablation as needed. Response to therapy was assessed by repeat PET scan and Holter monitor at three-monthly intervals. Optimal clinical response was defined as greater than 80 percent decline in PVC burden and resolution of uptake on PET scans. Suboptimal response was defined as less than 80 percent decrease in ventricular arrhythmia burden on cardiac monitoring with lack of PET resolution.

The cohort was composed of 41 percent men with 57±15 years and 47±11.8 percent left ejection fraction (LVEF). Myocarditis was seen in 51 percent (55/107) of PET scans. Cardiac MRI was correlative of PET in 27.4 percent of patients. In 47 percent of patients, PVC site of origin correlated with site of inflammation (maximal intensity). IST was started in 83.6 percent (46/55) of PET positive patients. There were 32 patients (69.5 percent) who received IST alone and 14 (30.5 percent) underwent IST and catheter ablation. 

Optimal response was seen in 76 percent (29/38) and suboptimal response was seen in 24 percent (9/38) over a mean follow up of 6±3 months. The data show 37 percent of patients who had left ventricular dysfunction ejection fraction (EF) improved (Δ13 ± 6 percent). Lymphocytic infiltrative myocarditis was the most common pathologic finding (46 percent, 13/28), biological markers were not diagnostic. Of the untreated patients, 67 percent (4/6) had worsening EF (Δ10 ± 4 percent) over six months of follow up.

Researchers said a randomized, control trial should be undertaken to assess the impact of IST in patients with PVCs and myocarditis. They said this would help better understand the etiopathogenesis and therapy strategies.

Find links to all the Heart Rhythm 2018 Late-breaking Studies

 

 

#HRS2018 #HRS18


Related Content

News | Cardiovascular Clinical Studies

May 23, 2024 — A newly-published peer-reviewed study in the Journal of the American Heart Association, JAHA, found that ...

Home May 23, 2024
Home
News | Cardiovascular Clinical Studies

May 23, 2024 — Global Heart Hub, the international alliance of heart patient organizations, announced the first findings ...

Home May 23, 2024
Home
News | Cardiovascular Clinical Studies

May 21, 2024 — A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging ...

Home May 21, 2024
Home
News | Cardiovascular Clinical Studies

May 20, 2024 — Cardiologist Brendan Carry, MD, and a team of Danville, PA-based Geisinger Medical Center physicians have ...

Home May 20, 2024
Home
News | Cardiovascular Clinical Studies

May 18, 2024 — Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ...

Home May 18, 2024
Home
News | Cardiovascular Clinical Studies

May 17, 2024 — Royal Philips, a global leader in health technology, is presenting new retrospective study results ...

Home May 17, 2024
Home
News | Cardiovascular Clinical Studies

May 15, 2024 — A new study demonstrated parity between a minimally invasive procedure to replace the aortic valve in the ...

Home May 15, 2024
Home
News | Cardiovascular Clinical Studies

May 14, 2024 — One of the most common genetic heart diseases worldwide, hypertrophic cardiomyopathy (HCM) causes the ...

Home May 14, 2024
Home
News | Cardiovascular Clinical Studies

May 14, 2024 — An ambitious, nationwide clinical trial led by UVA Health’s Karen Johnston, MD, has provided doctors with ...

Home May 14, 2024
Home
Subscribe Now